Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Axsome Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 04:00PM GMT
Release Date Price: €45.82
Esther P. Rajavelu
UBS Investment Bank, Research Division - Analyst & Executive Director

Good morning, everyone. Thank you for joining us at the UBS Virtual Healthcare Conference Day 1. I am excited to have Axsome management team here with us for a presentation. And I would love to turn the mic over to Herriot Tabuteau, CEO of Axsome.

Herriot Tabuteau
Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President

Well, thank you so much for having us present at your conference. This is our first year at the UBS conference. And this is an exciting time for Axsome. So this is a great time for us to be presenting. Now while Axsome is a CNS-focused company.

And before I get into that, I just want to go to Slide 2. So I will be making forward-looking statements, and I do encourage you to read our SEC filings for a full description of uncertainties associated with our business.

So as I mentioned, Axsome is CNS-focused. When the company was founded, the point of choosing this therapeutic area was that it was underserved at the time, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot